Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Covert

Nurse Practitioner Beloit, OH Nurse Practitioner

NPI 1912541103 CMS profile 11094823

18586 5Th St, Beloit, OH 44609

Open in the dashboard

General payments

$4,709

310 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Covert of Beloit, OH is reported in the CMS Open Payments database as having received $4,709 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $505 15
2024 General $54 2
2023 General $264 14
2022 General $2,022 127
2021 General $1,865 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Covert
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Melissa Covert were reported at $505. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Melissa Covert Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,865 $135 $40–$426 $132
2022 $2,022 $152 $48–$470 $149
2023 $264 $166 $54–$529 $160
2024 $54 $173 $55–$556 $164
2025 $505 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $665 43 payments
  2. Sanofi-Aventis U.S. LLC $590 33 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $576 38 payments
  4. Novo Nordisk Inc $564 38 payments
  5. Corcept Therapeutics $460 31 payments
  6. Esperion Therapeutics, Inc. $278 24 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $273 16 payments
  8. Amarin Pharma Inc. $244 30 payments
  9. Insulet Corporation $127 2 payments
  10. Novartis Pharmaceuticals Corporation $125 8 payments
  11. Other $807 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,709 310 payments
Products named General payments · program years 2021–2025
  1. JARDIANCE Diabetes $576 38 payments
  2. Korlym $460 31 payments
  3. TRULICITY $432 28 payments
  4. RYBELSUS $413 28 payments
  5. SOLIQUA 100/33 $377 26 payments
  6. JARDIANCE Diabetes $324 22 payments
  7. Ozempic $323 27 payments
  8. NEXLETOL $278 24 payments
  9. Kerendia $273 16 payments
  10. SYNJARDY $270 25 payments
  11. Other $2,563 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record